Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| macrophage | 22 studies | 36% ± 21% | |
| classical monocyte | 20 studies | 31% ± 13% | |
| endothelial cell | 19 studies | 35% ± 14% | |
| astrocyte | 18 studies | 53% ± 19% | |
| mast cell | 17 studies | 33% ± 15% | |
| microglial cell | 13 studies | 40% ± 15% | |
| oligodendrocyte | 12 studies | 36% ± 11% | |
| dendritic cell | 11 studies | 48% ± 14% | |
| monocyte | 11 studies | 40% ± 19% | |
| glutamatergic neuron | 11 studies | 44% ± 21% | |
| oligodendrocyte precursor cell | 11 studies | 40% ± 14% | |
| natural killer cell | 10 studies | 25% ± 9% | |
| GABAergic neuron | 10 studies | 42% ± 20% | |
| B cell | 10 studies | 28% ± 11% | |
| myeloid cell | 10 studies | 42% ± 17% | |
| fibroblast | 10 studies | 24% ± 6% | |
| T cell | 9 studies | 23% ± 8% | |
| pericyte | 9 studies | 28% ± 13% | |
| naive B cell | 8 studies | 19% ± 3% | |
| non-classical monocyte | 8 studies | 28% ± 9% | |
| conventional dendritic cell | 8 studies | 32% ± 14% | |
| neuron | 8 studies | 42% ± 19% | |
| adipocyte | 8 studies | 26% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 7 studies | 24% ± 8% | |
| amacrine cell | 7 studies | 48% ± 24% | |
| epithelial cell | 7 studies | 40% ± 23% | |
| retinal cone cell | 7 studies | 44% ± 21% | |
| mononuclear phagocyte | 6 studies | 29% ± 14% | |
| CD16-negative, CD56-bright natural killer cell, human | 6 studies | 24% ± 6% | |
| interneuron | 6 studies | 56% ± 14% | |
| retina horizontal cell | 6 studies | 46% ± 17% | |
| Mueller cell | 6 studies | 42% ± 21% | |
| endothelial cell of lymphatic vessel | 6 studies | 32% ± 7% | |
| smooth muscle cell | 6 studies | 24% ± 8% | |
| CD4-positive, alpha-beta T cell | 5 studies | 21% ± 4% | |
| retinal bipolar neuron | 5 studies | 32% ± 19% | |
| CD8-positive, alpha-beta T cell | 5 studies | 21% ± 4% | |
| regulatory T cell | 5 studies | 18% ± 4% | |
| type I pneumocyte | 5 studies | 29% ± 8% | |
| type II pneumocyte | 5 studies | 26% ± 9% | |
| basal cell | 5 studies | 33% ± 23% | |
| effector memory CD8-positive, alpha-beta T cell | 4 studies | 21% ± 2% | |
| hematopoietic precursor cell | 4 studies | 33% ± 16% | |
| granule cell | 4 studies | 51% ± 6% | |
| cardiac muscle cell | 4 studies | 32% ± 3% | |
| lymphocyte | 4 studies | 40% ± 12% | |
| retinal rod cell | 4 studies | 61% ± 11% | |
| GABAergic interneuron | 3 studies | 38% ± 11% | |
| glial cell | 3 studies | 28% ± 12% | |
| megakaryocyte | 3 studies | 43% ± 26% | |
| pro-B cell | 3 studies | 21% ± 3% | |
| plasma cell | 3 studies | 36% ± 6% | |
| ciliated cell | 3 studies | 22% ± 6% | |
| GABAergic amacrine cell | 3 studies | 56% ± 9% | |
| OFF-bipolar cell | 3 studies | 45% ± 20% | |
| ON-bipolar cell | 3 studies | 51% ± 22% | |
| glycinergic amacrine cell | 3 studies | 55% ± 6% | |
| rod bipolar cell | 3 studies | 38% ± 19% | |
| intermediate monocyte | 3 studies | 37% ± 20% | |
| endothelial cell of vascular tree | 3 studies | 35% ± 18% | |
| connective tissue cell | 3 studies | 25% ± 4% | |
| ependymal cell | 3 studies | 36% ± 20% | |
| neutrophil | 3 studies | 38% ± 17% | |
| leukocyte | 3 studies | 30% ± 10% | |
| alveolar macrophage | 3 studies | 49% ± 14% | |
| club cell | 3 studies | 31% ± 12% | |
| respiratory goblet cell | 3 studies | 30% ± 14% | |
| plasmacytoid dendritic cell | 3 studies | 21% ± 7% | |
| mural cell | 3 studies | 43% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2006.94 | 1443 / 1445 | 100% | 29.08 | 183 / 183 |
| breast | 100% | 1862.30 | 459 / 459 | 100% | 28.08 | 1116 / 1118 |
| skin | 100% | 3311.37 | 1809 / 1809 | 100% | 47.10 | 471 / 472 |
| brain | 100% | 2176.02 | 2635 / 2642 | 99% | 21.04 | 696 / 705 |
| bladder | 100% | 1311.14 | 21 / 21 | 98% | 21.92 | 495 / 504 |
| stomach | 100% | 1147.94 | 358 / 359 | 98% | 16.33 | 280 / 286 |
| uterus | 100% | 1426.27 | 170 / 170 | 98% | 21.61 | 448 / 459 |
| lung | 100% | 2106.30 | 577 / 578 | 98% | 22.33 | 1129 / 1155 |
| intestine | 100% | 1516.75 | 966 / 966 | 97% | 14.72 | 512 / 527 |
| prostate | 100% | 1395.53 | 245 / 245 | 97% | 13.59 | 486 / 502 |
| ovary | 100% | 1621.83 | 180 / 180 | 91% | 14.80 | 391 / 430 |
| thymus | 100% | 1219.33 | 652 / 653 | 91% | 12.12 | 550 / 605 |
| kidney | 99% | 897.01 | 88 / 89 | 79% | 8.79 | 713 / 901 |
| pancreas | 81% | 515.91 | 265 / 328 | 97% | 12.42 | 172 / 178 |
| adrenal gland | 100% | 1256.35 | 258 / 258 | 77% | 7.69 | 176 / 230 |
| liver | 79% | 479.14 | 179 / 226 | 55% | 5.31 | 225 / 406 |
| adipose | 100% | 1721.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2848.10 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 29.11 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 11.50 | 1 / 1 |
| muscle | 99% | 1840.79 | 795 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 99% | 21.65 | 79 / 80 |
| blood vessel | 98% | 951.56 | 1314 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 2432.06 | 912 / 929 | 0% | 0 | 0 / 0 |
| heart | 97% | 1010.25 | 838 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 12.38 | 26 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0010468 | Biological process | regulation of gene expression |
| GO_1902682 | Biological process | protein localization to pericentric heterochromatin |
| GO_0060816 | Biological process | random inactivation of X chromosome |
| GO_0060044 | Biological process | negative regulation of cardiac muscle cell proliferation |
| GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
| GO_0001889 | Biological process | liver development |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0048536 | Biological process | spleen development |
| GO_0060038 | Biological process | cardiac muscle cell proliferation |
| GO_0048538 | Biological process | thymus development |
| GO_0140718 | Biological process | facultative heterochromatin formation |
| GO_0007417 | Biological process | central nervous system development |
| GO_0048863 | Biological process | stem cell differentiation |
| GO_0010614 | Biological process | negative regulation of cardiac muscle hypertrophy |
| GO_0035097 | Cellular component | histone methyltransferase complex |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0035098 | Cellular component | ESC/E(Z) complex |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0003677 | Molecular function | DNA binding |
| GO_0003682 | Molecular function | chromatin binding |
| GO_0046976 | Molecular function | histone H3K27 methyltransferase activity |
| GO_0032452 | Molecular function | histone demethylase activity |
| GO_0061649 | Molecular function | ubiquitin-modified histone reader activity |
| GO_0043130 | Molecular function | ubiquitin binding |
| Gene name | JARID2 |
| Protein name | Protein Jumonji (Jumonji/ARID domain-containing protein 2) |
| Synonyms | JMJ |
| Description | FUNCTION: Regulator of histone methyltransferase complexes that plays an essential role in embryonic development, including heart and liver development, neural tube fusion process and hematopoiesis . Acts as an accessory subunit for the core PRC2 (Polycomb repressive complex 2) complex, which mediates histone H3K27 (H3K27me3) trimethylation on chromatin . Binds DNA and mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells, thereby playing a key role in stem cell differentiation and normal embryonic development . In cardiac cells, it is required to repress expression of cyclin-D1 (CCND1) by activating methylation of 'Lys-9' of histone H3 (H3K9me) by the GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases (By similarity). Also acts as a transcriptional repressor of ANF via its interaction with GATA4 and NKX2-5 (By similarity). Participates in the negative regulation of cell proliferation signaling (By similarity). Does not have histone demethylase activity (By similarity). . |
| Accessions | ENST00000341776.7 [Q92833-1] Q92833 ENST00000397311.4 [Q92833-3] |